Abstract: The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.

Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a secreted activator of the immune response, to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.

Abstract: Disclosed herein are compositions comprising an isolated cellulose degrading fungus and pharmaceutical substances produced by the fungus.

Abstract: Phosphodiesterase-4 (PDE4) inhibiting compositions comprising a Sceletium and an activity enhancer are disclosed and described. Methods and systems for inhibiting PDE4, as well as, dosage forms comprising a Sceletium extract and an activity enhancer are also disclosed. Additionally disclosed are methods for enhancing the potency or PDE4 inhibitory activity of a Sceletium extract by addition of an activity enhancer.

Abstract: Phosphodiesterase (PDE) such as phosphodiesterase type V (PDE5) inhibiting compositions comprising a Sceletium extract are disclosed and described. Methods and systems for inhibiting PDE, as well as, dosage forms comprising a Sceletium extract are also disclosed. Additionally disclosed are methods for enhancing the potency or PDE inhibitory activity of a Sceletium extract by addition of an activity enhancer.

Abstract: The present invention is a method of preparing and potentiating functional foods and, in particular, herbs by subjecting the food or herb to specific method steps, either a particular three- or four-step potentiating process or a specific infusion/fermentation potentiating technique, for which in some embodiments the fermentation is optional.

Abstract: The invention relates to the use of tomatoes for inhibition, amelioration or prevention of adipogenesis mediated diseases such as obesity, lipid storage disease and hyperlipemia. Provided is a tomato plant, fruit, fragment or extract thereof for use in a method for preventing weight gain, and/or inhibiting, preventing or ameliorating a disease condition associated with adipogenesis in a mammal, wherein the tomato is a ripening-impaired mutant tomato, such as a ripening inhibitor (rin), nonripening (nor), and/or never ripe (Nr) gene mutant tomato. Also provided are anti-adipogenic extracts and compositions comprising the extract.

Abstract: A method of treating telangiectasia in a subject in need thereof is disclosed. The method includes topically applying to skin of said subject in need of treatment of telangiectasia a composition comprising effective amounts of an alcoholic extract of Centella asiactica leaf and an aqueous extract of Vitis vinifera seed to disrupt endothelia tubes in skin.

Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

Abstract: Composition comprising a metal and/or a semimetal, a sodium salt, a tranquilizer, a halogen, a carotenoid, grain, and a neutral gel for example for use in treating and/or preventing a condition, disorder or disease such as pain, metabolic diseases, fatigue, absence of appetite, cramps, immune diseases, inflammatory disease, cancer, neurological and/or psychiatric diseases.

Abstract: A nutraceutical composition comprising water having an alkaline pH and a plurality of members of the group consisting of orange extract, vanilla extract, apple honey, agave syrup, apple cider vinegar, olive oil, coconut oil, liquid multivitamin, aloe vera juice, flax seed oil, hemp oil, and elephant garlic, wherein each of the plurality of members is present in an amount effective to ameliorate the effects of inflammation and raise energy levels when administered to a mammal.

Abstract: A Chinese medicine prescription capable of treating lung adenocarcinoma is composed of Polygala tenuifolia Willd, atractylodes macrocephala, angelica sinensis, poria pararadicis, astragalus membranaceus, ziziphus jujaba Mill.var.spinosa, codonopsis pilosula, costustoot, radix glycyrrhizae preparata and fresh ginger, and a pharmaceutical residue is filtered and obtained after a water quenching procedure of the aforementioned herbs to provide a water-quenched medicine soup, and a pharmaceutical residue is filtered and obtained after processing the water-quenched pharmaceutical residue by a liquor quenching procedure to obtain a liquor-quenched medicine soup; and the water-quenched medicine soup and the liquor-quenched medicine soup are mixed. The prescription is capable of triggering cell autophagy and reducing cell growth, expansion and metastasis, so as to achieve the effect of lung adenocarcinoma treatment.

Abstract: Compositions and methods for the treatment of malignancy are disclosed.

Abstract: A composition and method for treatment and protecting against influenza that includes bioactive Substance P and/or its analogs. The composition agents can be administered via inhalation therapy, intravenously, intramuscularly, sublingually, or by other methods.

Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.

Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.

Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.

Abstract: The present application relates to the reproductive management of cattle, and more particularly, to the synchronization of estrous cycles and ovulation for fixed time artificial insemination of cattle with the addition of a second prostaglandin treatment in Ovsynch-type protocols resulting in the complete regression of the corpus luteum and an increase in pregnancies per artificial insemination in multiparous cows.

Abstract: Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1. MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases.

Abstract: The present invention encompasses an antithrombotic nanoparticle and use thereof.

Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, Immune complexed IgG to IgG F?R binding, and immune complexed IgG mC1q (membrane C1q) or soluble C1q binding. Such compounds may have therapeutic use in treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD).

Abstract: A stable suspension of teicoplanin and one or more pharmaceutically acceptable additives and method for preparation wherein the teicoplanin is mixed with an aqueous or non aqueous suspension base and pharmaceutically acceptable additives and wherein the teicoplanin is milled to obtain a homogeneously dispersed suspension.

Abstract: The present invention relates to a method for preventing or treating virus and protozoa infection in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (SBP)-tagged immunostimulatory protein and a SBP-binding matrix, wherein the immunostimulatory protein is from Ganoderma species. The present invention also relates to a method for inducing interferon-gamma production in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (SBP)-tagged immunostimulatory protein and a SBP-binding matrix, wherein the immunostimulatory protein is from Ganoderma species.

Abstract: The present invention relates to nanoparticle aggregates comprising osteopontin (OPN) and one or more particles containing calcium and/or strontium and to their use for reducing or preventing biofilm growth or for removing biofilm. The invention furthermore relates to the use of the nanoparticle aggregates for treating, alleviating or preventing biofilm-related diseases.

Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.

Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing.

Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.

Abstract: The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus (SARS), pandemic Influenza A H5N1 (avian influenza) and pandemic influenza A H1N1 (swine 'flu).

Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.

Abstract: A method for treating a patient having diabetes which involves treating the patient with multiple rounds of a stem cell mobilization agent wherein, for each cycle of treatment, the patient's glucose level is reduced to a lower level than prior to treatment. Each cycle involves: a. exposing the patient to a stem cell proliferation agent for a first treatment period; b. providing a first waiting period during which no active treatment is conducted; c. exposing the patient to a stem cell proliferation agent for a second treatment period; d. providing a second waiting period during which no active treatment is conducted; e. exposing the patient to a stem cell proliferation agent for a third treatment period; whereby the patient's blood glucose level begins trending lower subsequent to initiation of treatment and continues to trend lower after active treatment has ended.

Abstract: It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped.

Abstract: A method for treating, remedying, or preventing psoriasis by administering a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing psoriasis by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation.

Abstract: Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures. Also disclosed are PTHrP or analogues thereof, such as abaloparatide, for increasing BMD and/or TBS in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to increase BMD and/or TBS.

Abstract: The present invention provides a novel albumin-free preparation of Factor VIII has a high amount of salt and a low concentration of sugar and of glycine. The high salt provides stability and an elegant cake structure as the major crystalline component. The sugar and glycine provide a complex amorphous matrix together with some amorphous non-crystallized salt for stabilization of Factor VIII. This formulation is suitable for B-domain deleted Factor VIII that requires a high ionic strength environment for stability. The addition of low amount of glycine to the sucrose prevents the crystallization of salt. This results in an amorphous matrix comprising of glycine, sucrose, and salt. This amorphous matrix provides a stabilizing environment where Factor VIII is protected by three stabilizers; amino acid (glycine), sugar (sucrose or trehalose), and salt (NaCl). Such an amorphous matrix that can stabilize the Factor VIII across lyophilization and during storage as a lyophile.

Abstract: The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.

Abstract: The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof.

Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.

Abstract: The invention provides reagents and methods for enzyme replacement therapy using chemically modified species of human cystathionine ?-synthase (CBS) to treat homocystinuria and other related diseases and disorders.

Abstract: Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an al antitrypsin (AAT) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of ?1-antitrypsin.

Abstract: The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.

Abstract: The present invention relates to TSCM cells and uses thereof. TSCM cells can be used help identify and treat patients who are likely to experience particular treatment outcomes. In other embodiments TSCM cells are generated in vitro and used for adoptive transfer therapy.

Abstract: The invention describes immunotherapies for treating various cancers in nervous system, particularly brain cancer. In various embodiments, the method may comprise: obtaining a tumor tissue from the subject; preparing a tumor cell lysate from the tumor tissue; isolating an immune cell from the subject; priming the immune cell against the tumor cell lysate. In various embodiments, intraventricular delivery of dendritic cells for brain cancer immunotherapy is disclosed.

Abstract: The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.

Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the RAS protein, but has one to three point mutations thereof. The at least one peptide is for use in the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent.

Abstract: A live attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional evpB protein and a method of using the same to protect fish against infection from virulent Edwardsiella ictaluri. The methods and compositions for protecting fish against infection from virulent Edwardsiella ictaluri comprising administering to a fish a therapeutically effective amount of an attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional EvpB protein. The bacterium may include an insertion and/or deletion mutation in the evpB gene. The fish include catfish, preferably catfish fingerling or a catfish fry. The composition may be delivered via immersion delivery, an injection delivery, an oral delivery, or combinations thereof.

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.

Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.